JP7499789B2 - 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤 - Google Patents

慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤 Download PDF

Info

Publication number
JP7499789B2
JP7499789B2 JP2021567619A JP2021567619A JP7499789B2 JP 7499789 B2 JP7499789 B2 JP 7499789B2 JP 2021567619 A JP2021567619 A JP 2021567619A JP 2021567619 A JP2021567619 A JP 2021567619A JP 7499789 B2 JP7499789 B2 JP 7499789B2
Authority
JP
Japan
Prior art keywords
amino
carbonyl
carboxamide
benzimidazole
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021567619A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021132472A1 (https=
JPWO2021132472A5 (https=
Inventor
賢 岡本
麻希 栗田
浩史 山口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of JPWO2021132472A1 publication Critical patent/JPWO2021132472A1/ja
Publication of JPWO2021132472A5 publication Critical patent/JPWO2021132472A5/ja
Priority to JP2024090606A priority Critical patent/JP7779953B2/ja
Application granted granted Critical
Publication of JP7499789B2 publication Critical patent/JP7499789B2/ja
Priority to JP2025199177A priority patent/JP2026015542A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2021567619A 2019-12-25 2020-12-24 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤 Active JP7499789B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024090606A JP7779953B2 (ja) 2019-12-25 2024-06-04 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤
JP2025199177A JP2026015542A (ja) 2019-12-25 2025-11-19 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019233865 2019-12-25
JP2019233865 2019-12-25
PCT/JP2020/048479 WO2021132472A1 (ja) 2019-12-25 2020-12-24 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090606A Division JP7779953B2 (ja) 2019-12-25 2024-06-04 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤

Publications (3)

Publication Number Publication Date
JPWO2021132472A1 JPWO2021132472A1 (https=) 2021-07-01
JPWO2021132472A5 JPWO2021132472A5 (https=) 2024-04-30
JP7499789B2 true JP7499789B2 (ja) 2024-06-14

Family

ID=76575232

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021567619A Active JP7499789B2 (ja) 2019-12-25 2020-12-24 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤
JP2024090606A Active JP7779953B2 (ja) 2019-12-25 2024-06-04 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤
JP2025199177A Pending JP2026015542A (ja) 2019-12-25 2025-11-19 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024090606A Active JP7779953B2 (ja) 2019-12-25 2024-06-04 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤
JP2025199177A Pending JP2026015542A (ja) 2019-12-25 2025-11-19 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤

Country Status (16)

Country Link
US (1) US12599589B2 (https=)
EP (1) EP4082573A4 (https=)
JP (3) JP7499789B2 (https=)
KR (1) KR20220120646A (https=)
CN (2) CN119303087A (https=)
AU (1) AU2020413313B2 (https=)
BR (1) BR112022012485A2 (https=)
CA (1) CA3165891A1 (https=)
CO (1) CO2022010343A2 (https=)
EC (1) ECSP22058286A (https=)
IL (1) IL294191A (https=)
MX (1) MX2022007936A (https=)
PE (1) PE20230164A1 (https=)
PH (1) PH12022551578A1 (https=)
UA (1) UA130283C2 (https=)
WO (1) WO2021132472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082247B (zh) * 2023-01-19 2025-08-01 浙江工业大学 一种苯并咪唑类衍生物及其应用
CN121401398A (zh) * 2025-12-29 2026-01-27 汕头市中心医院 一种实验性自身免疫性前列腺炎大鼠模型的构建方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024898A1 (ja) 2011-08-18 2013-02-21 日本新薬株式会社 ヘテロ環誘導体及び医薬
JP2013508325A (ja) 2009-10-23 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ミクロソームプロスタグランジンｅ２シンターゼ−１のインヒビター
JP2015501784A (ja) 2011-11-04 2015-01-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 治療の方法
WO2017073709A1 (ja) 2015-10-29 2017-05-04 あすか製薬株式会社 ピリミジン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508325A (ja) 2009-10-23 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ミクロソームプロスタグランジンｅ２シンターゼ−１のインヒビター
WO2013024898A1 (ja) 2011-08-18 2013-02-21 日本新薬株式会社 ヘテロ環誘導体及び医薬
JP2015501784A (ja) 2011-11-04 2015-01-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 治療の方法
WO2017073709A1 (ja) 2015-10-29 2017-05-04 あすか製薬株式会社 ピリミジン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAUSCH B. et al.，Canephron(R) N reduces pain in experimental cystitis and prostatitis putatively by inhibition of PGE，European Urology Supplements，2016年，Vol. 15, No. 3，p. e262，Abstract No. 262

Also Published As

Publication number Publication date
ECSP22058286A (es) 2022-09-30
JP2024103724A (ja) 2024-08-01
JP2026015542A (ja) 2026-01-29
MX2022007936A (es) 2022-10-27
PE20230164A1 (es) 2023-02-01
CA3165891A1 (en) 2021-07-01
BR112022012485A2 (pt) 2022-09-06
AU2020413313B2 (en) 2025-11-27
EP4082573A4 (en) 2024-01-10
JPWO2021132472A1 (https=) 2021-07-01
NZ789736A (en) 2025-10-31
CO2022010343A2 (es) 2022-10-31
JP7779953B2 (ja) 2025-12-03
US12599589B2 (en) 2026-04-14
US20230094705A1 (en) 2023-03-30
CN114867495A (zh) 2022-08-05
AU2020413313A1 (en) 2022-07-14
PH12022551578A1 (en) 2023-11-29
WO2021132472A1 (ja) 2021-07-01
EP4082573A1 (en) 2022-11-02
CN119303087A (zh) 2025-01-14
KR20220120646A (ko) 2022-08-30
UA130283C2 (uk) 2026-01-07
CN114867495B (zh) 2024-10-18
IL294191A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
JP7779953B2 (ja) 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤
JP5735987B2 (ja) 窒素含有へテロアリール誘導体
KR102155559B1 (ko) 암, 자가면역성 염증 및 중추신경계 장애를 치료하기 위한 비플루오로디옥살란-아미노-벤즈이미다졸 키나제 억제제
US20050009876A1 (en) Indazole compounds, compositions thereof and methods of treatment therewith
KR20230015343A (ko) 할로겐화된-헤테로아릴 및 다른 헤테로사이클릭 키나제 억제제, 및 이의 용도
JP2025182108A (ja) 免疫チェックポイント阻害剤と併用で用いる抗腫瘍薬
JP2025122672A (ja) 固体分散体、固体分散体を含む製剤、及びそれらの製造方法
RU2836236C1 (ru) Профилактическое и/или терапевтическое средство против хронического простатита/синдрома хронической тазовой боли
WO2025090727A1 (en) Compounds that mediate protein degradation and methods of use thereof
HK40081072A (en) Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome
RU2780168C1 (ru) Новое производное пиридо [3,4-d] пиримидин-8-она, обладающее ингибирующей протеинкиназы активностью, и фармацевтическая композиция для предупреждения, облегчения или лечения рака, содержащее указанное выше
RU2842861C1 (ru) Противоопухолевое средство для применения в комбинации с ингибитором иммунных контрольных точек
TWI480276B (zh) 作為蛋白質激酶抑制劑之化合物及組合物
US20240285621A1 (en) Pyrazolyl-pyrimidine derivatives as kinase inhibitors
CN117777124A (zh) Parp选择性抑制剂
EA043328B1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
HK1191936B (en) Compounds and compositions as protein kinase inhibitors
HK1191936A (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220726

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231031

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240604

R150 Certificate of patent or registration of utility model

Ref document number: 7499789

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150